Journal article
A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008
SM Lingaratnam, SW Kirsa, JD Mellor, J Jackson, W Crellin, M Fitzsimons, JR Zalcberg
Australian Health Review | CSIRO PUBLISHING | Published : 2011
DOI: 10.1071/AH10894
Abstract
Objective. To describe the current practices and policy of Australian private health insurance (PHI) companies with respect to cover for pharmaceuticals not subsidised under the Pharmaceutical Benefits Scheme (PBS). Design, setting and participants. A 2008 review of web-published policy statements for top-level hospital and comprehensive general treatment insurance, and survey of reimbursement practices by way of questionnaire, of 31 Australian-registered, open-membership PHI companies. Main outcome measures(s). Description of the level of pharmaceutical cover and important considerations identified by PHI companies for funding non-PBS pharmaceuticals through benefit entitlements or ex-grati..
View full abstractGrants
Funding Acknowledgements
[ "Roche Products (Australia) Pty Ltd provided an unrestricted research grant to the Peter MacCallum Cancer Centre. At no time did Roche Products (Australia) Pty Ltd influence any part of the study. Roche had no direct involvement in the conception, scoping, execution or publication of any part of this work. The authors declare that no other conflicts of interest exist.", "We thank Ken Gray from the Pharmacy Guild of Australia (Victoria Branch) for his support in the steering committee, and Roche Products (Australia) Pty Ltd (Dee Why, NSW) for providing an unrestricted research grant to carry out this study. The unrestricted research grant was paid to the Peter MacCallum Cancer Centre and this was utilised to fund a part-time research officer to complete the project." ]